Viracta Therapeutics
2533 S. Coast Hwy 101
Suite 210
Cardiff
California
92007
United States
Website: http://www.viracta.com/
81 articles with Viracta Therapeutics
-
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
1/19/2023
Viracta Therapeutics, Inc. today announced that the European Commission (EC) has granted an orphan drug designation (ODD) to Viracta’s all-oral combination product candidate, Nana-val (nanatinostat and valganciclovir), for the treatment of diffuse large B-cell lymphoma (DLBCL).
-
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
1/8/2023
Viracta Therapeutics, Inc. announced new clinical data from the Phase 1b/2 trial of Nana-val in patients with EBV+ R/M NPC and other EBV+ solid tumors and outlined its key 2023 clinical objectives.
-
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
11/30/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
-
Viracta Therapeutics Announces New Employment Inducement Grant - November 21, 2022
11/21/2022
Viracta Therapeutics, Inc. announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 90,000 shares of common stock.
-
Viracta Therapeutics Announces New Employment Inducement Grant - November 14, 2022
11/14/2022
Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 80,000 shares of common stock.
-
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
11/10/2022
Viracta Therapeutics, Inc. reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.
-
Viracta Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/2/2022
Viracta Therapeutics, Inc. announced that company leadership is scheduled to present and participate in one-on-one meetings at four investor conferences in November.
-
Seven biopharma companies are under new leadership. This week's Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
-
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth
9/19/2022
Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer.
-
Viracta Therapeutics Announces New Employment Inducement Grant - September 19, 2022
9/19/2022
Viracta Therapeutics, Inc. announced that, in connection with the appointment of Mark Rothera as Viracta’s new President and Chief Executive Officer, the independent members of Viracta’s Board of Directors approved the grant of a non-qualified stock option to Mr. Rothera to purchase 1,375,000 shares of common stock.
-
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
9/7/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced that the European Commission has granted an orphan drug designation (ODD) to nanatinostat and valganciclovir (Nana-val), the company's all-oral combination product candidate, for the treatment of peripheral T-cell lymphoma (PTCL).
-
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
8/16/2022
Viracta Therapeutics, Inc. today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy , Ph.D., to its Governing Board.
-
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
8/11/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.
-
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
8/9/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.
-
Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award
6/13/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston , M.D., is being presented with the Science History Institute's Biotechnology Heritage Award.
-
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
6/2/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Safety Monitoring Committee for the ongoing Phase 1b /2 study of Nana-val.
-
Viracta Therapeutics to Present at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 1:30 p.m. EDT.
-
Viracta Therapeutics Announces New Employment Inducement Grant - May 13, 2022
5/13/2022
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 110,000 shares of common stock.
-
Viracta Therapeutics to Present at Upcoming May 2022 Investor Conferences
5/11/2022
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management will present and participate in one-on-one meetings at the following investor conferences in May.
-
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
5/10/2022
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the first quarter of 2022 and provided an update on recent corporate progress.